Food News and Research

RSS

Genome is one more factor to blame for unwanted pounds

In addition to fast food, desk jobs, and inertia, there is one more thing to blame for unwanted pounds-our genome, which has apparently not caught up with the fact that we no longer live in the Stone Age.

16 Dec 2010

Discovery Labs awarded NIH Fast Track SBIR grant for developing aerosolized KL4 surfactant for RDS

Discovery Laboratories, Inc. today announced that the Company has been awarded Phase I of a Fast Track Small Business Innovation Research Grant (SBIR) from the National Institutes of Health (NIH) to support the development of the Company's program for aerosolizing KL4 surfactant for neonatal respiratory distress syndrome (RDS).

16 Dec 2010

Amarin completes patient randomization in AMR101 Phase 3 trial in patients with high triglyceride levels

Amarin Corporation plc, a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today reported the completion of patient randomization for its ANCHOR trial, a pivotal Phase 3 trial of AMR101. The Company indicated that it anticipates reporting top-line results from this trial in Q2 2011.

16 Dec 2010

Rite Aid third quarter net loss decreases to $79.1 million

Rite Aid Corporation today reported financial results for its third fiscal quarter ended November 27, 2010.

16 Dec 2010

Adeona expands and enhances zinc-based product candidate portfolio

Adeona Pharmaceuticals, Inc., a developer of innovative medicines for serious central nervous system diseases, announced today that it has acquired access to clinical data supporting a zinc-based therapy for the prevention of infections in the elderly. This acquisition expands and enhances Adeona's zinc-based product candidate portfolio that already includes its proprietary zinc-based tablets for use in the dietary management of mild to moderate Alzheimer's disease and mild cognitive impairment patients, and age-related macular degeneration.

16 Dec 2010

Harmful ingredients in toxic toys need to banned

Manufacturer recalls of toys, promotional drinking glasses, and other children's products constitute an ongoing "toxic toys crisis" that requires banning potentially harmful ingredients in these products and other changes in policy and practices. That's the conclusion of a new analysis in ACS' journal Environmental Science & Technology.

16 Dec 2010

BELLUS Health, Celtic Therapeutics initiate KIACTA global confirmatory phase III clinical study for AA amyloidosis

BELLUS Health Inc. and Celtic Therapeutics announced today that a global confirmatory phase III clinical study was initiated on December 14, 2010 for KIACTA™ (eprodisate). KIACTA™ is a drug candidate being developed for the treatment of AA amyloidosis, a life-threatening orphan disease that occurs in patients with long-lasting inflammatory conditions, most commonly due to rheumatoid arthritis. The study is designed to confirm the safety and efficacy of KIACTA™ in preventing renal function decline in patients with AA amyloidosis.

16 Dec 2010

ADA supports FDA panel's recommendation for continuing review of existing, new scientific information

The American Dental Association today praised a Food and Drug Administration advisory panel's finding that the FDA acted appropriately when it ruled last year that dental amalgam is a safe and effective treatment option for the general population.

16 Dec 2010

CEL-SCI receives Ukraine government approval for Multikine Phase III clinical trial in head and neck cancer

CEL-SCI Corporation announced today it has received governmental approval from the Health Authority, Ministry of Health of Ukraine, to begin enrollment of subjects for a Phase III clinical trial of Multikine® in Ukraine. Multikine is the Company's flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer. Ukraine is one of nine countries to participate in this global Phase III trial. The Phase III trial will be run at about 48 clinical centers, of which about 6 centers will be in Ukraine.

16 Dec 2010

ADVENTRX seeks meeting with FDA to discuss ANX-514 docetaxel emulsion study findings

ADVENTRX Pharmaceuticals, Inc. today announced it has submitted a request to the U.S. Food and Drug Administration (FDA) to schedule a meeting for the purpose of discussing its product candidate ANX-514 (docetaxel emulsion for injection). The FDA is expected to set the meeting date within 60 days of receiving the request from ADVENTRX.

16 Dec 2010

Opinions: Kangaroo care; NTDs, Women's health

New York Times contributing writer Tina Rosen, on the newspaper's "Opinionator" blog, examines the success of a system known as kangaroo care, which has helped to improve the survival rates of premature infants by using skin-to-skin contact with mothers in place of incubators in low-resource settings. The post notes the potential value of such a strategy in poor countries "where pregnant women are unlikely to get the food and care they need," and "low birth weight babies are very common."

16 Dec 2010

CAMY reports 71% increase in youth exposure to alcohol ads

Youth exposure to alcohol advertising on U.S. television increased 71 percent between 2001 and 2009, according to a report released today by the Center on Alcohol Marketing and Youth at the Johns Hopkins Bloomberg School of Public Health.

16 Dec 2010

Three-day African food security forum opens in Accra

The 26th Annual Meeting of the Food Crisis Prevention Network, "which serves as the platform for deliberation on food production and food security in Africa," opened on Tuesday in Accra, Ghana, the Ghana News Agency reports. The three-day forum will examine "the agricultural and food situation for the 2010/2011 cropping season and come out with measures on tackling food crises," according to the news service.

16 Dec 2010

BPA exposure reduces quality of womens' eggs retrieved for IVF

A small-scale University of California, San Francisco-led study has identified the first evidence in humans that exposure to bisphenol A (BPA) may compromise the quality of a woman's eggs retrieved for in vitro fertilization (IVF). As blood levels of BPA in the women studied doubled, the percentage of eggs that fertilized normally declined by 50 percent, according to the research team.

16 Dec 2010

Ocera completes two studies of OCR-002 in patients with hyperammonemia, hepatic encephalopathy

Ocera Therapeutics, Inc. announced today that it has completed two studies evaluating the safety and pharmacokinetics of OCR-002 (ornithine phenylacetate) which includes healthy volunteers and patients with liver cirrhosis. OCR-002 recently received Orphan Drug status and Fast Track designation by the United States Food and Drug Administration for the treatment of hyperammonemia (excessive ammonia levels) and resultant Hepatic encephalopathy.

16 Dec 2010

FDA grants marketing clearance to Accuray's CyberKnife VSI System Lung Optimized Treatment

Accuray Incorporated, a global leader in the field of radiosurgery, announced today that the U.S. Food and Drug Administration (FDA) has granted the company 510(k) clearance to market Lung Optimized Treatment, a new component of the CyberKnife® VSI™ System. The 510(k) clearance enables Accuray to provide physicians with greater flexibility in delivering radiosurgery treatments to patients with lung cancer, the most common and deadly cancer worldwide.

15 Dec 2010

AmoyDx receives SFDA approval for its EGFR and BRAF mutations detection kits

Amoy Diagnostics announced today that its EGFR and BRAF mutation detection kits received market approval from China's State Food and Drug Administration (SFDA). The SFDA is the competent authority for regulating drugs and in vitro diagnostics in mainland China. The approval allows AmoyDx to market the EGFR and BRAF tests for clinical use in China.

15 Dec 2010

RPCI forms Photolitec to develop photosensitizing compounds used in photodynamic therapy

Roswell Park Cancer Institute (RPCI) on December 13, 2010, announced the formation of Photolitec, LLC, a new life-sciences company at RPCI that will develop photosensitizing compounds used in photodynamic therapy (PDT). PDT is an innovative cancer treatment pioneered at RPCI by scientist Thomas J. Dougherty, Chief Emeritus of the Institute's Photodynamic Therapy Center.

15 Dec 2010

Researchers introduce new class of drugs for HCV patients

To improve the care for individuals infected with the hepatitis C virus, a major health problem and a leading cause of chronic liver disease around the world, nearly 200 international hepatitis experts have taken an important step in escalating the introduction of a new class of targeted therapies for HCV – direct-acting antivirals.

15 Dec 2010

New device gathers reliable data about risky sexual behavior among Ethiopian teenagers

Brown University sociologists have developed a device to gather more reliable data about risky sexual behavior among Ethiopian teenagers and young adults than conventional face-to-face interviews can produce.

15 Dec 2010

Food News and Research

Genome is one more factor to blame for unwanted pounds

Discovery Labs awarded NIH Fast Track SBIR grant for developing aerosolized KL4 surfactant for RDS

Amarin completes patient randomization in AMR101 Phase 3 trial in patients with high triglyceride levels

Rite Aid third quarter net loss decreases to $79.1 million

Adeona expands and enhances zinc-based product candidate portfolio

Harmful ingredients in toxic toys need to banned

BELLUS Health, Celtic Therapeutics initiate KIACTA global confirmatory phase III clinical study for AA amyloidosis

ADA supports FDA panel's recommendation for continuing review of existing, new scientific information

CEL-SCI receives Ukraine government approval for Multikine Phase III clinical trial in head and neck cancer

ADVENTRX seeks meeting with FDA to discuss ANX-514 docetaxel emulsion study findings

Opinions: Kangaroo care; NTDs, Women's health

CAMY reports 71% increase in youth exposure to alcohol ads

Three-day African food security forum opens in Accra

BPA exposure reduces quality of womens' eggs retrieved for IVF

Ocera completes two studies of OCR-002 in patients with hyperammonemia, hepatic encephalopathy

FDA grants marketing clearance to Accuray's CyberKnife VSI System Lung Optimized Treatment

AmoyDx receives SFDA approval for its EGFR and BRAF mutations detection kits

RPCI forms Photolitec to develop photosensitizing compounds used in photodynamic therapy

Researchers introduce new class of drugs for HCV patients

New device gathers reliable data about risky sexual behavior among Ethiopian teenagers

Understanding cultivated meat and its global potential eBook

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Latest News